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Abstract
Background: Hepatitis B virus (HBV) infection is a major global health burden with distinct geographic public health
significance. Oman is a country with intermediate HBV carrier prevalence; however, little is known about the incidence of
HBV variants in circulation. We investigated the HBV genotype distribution, the occurrence of antiviral resistance, and HBV
surface antigen (HBsAg) escape mutations in HBsAg-positive patients in Oman.
Methods: Serum samples were collected from 179 chronically HBV-infected patients enrolled in various gastroenterology
clinics in Oman. HBV genotypes were determined by sequencing and phylogenetic analysis. Mutations in the HBV
polymerase and the HBsAg gene were characterized by mutational analysis.
Results: HBV genotypes D (130/170; 76.47%) and A (32/170; 18.28%) are predominant in Oman. The HBV genotypes C and E
were less frequent (each 1.18%), while the HBV genotypes B, G, F, and H were not detected. Four patients revealed HBV
genotype mixtures (HBV-A/D and D/C). The analyses of vaccine escape mutations yield that 148/170 (87.06%) HBV
sequences were wild type. 22/170 (12.94%) HBV sequences showed mutations in the ‘‘a’’ determinant of the HBsAg domain.
Two patients showed the described HBV vaccine escape mutation sP120T. 8/146 (5.48%) HBV isolates harbored mutations in
the HBV polymerase known to confer resistance against antiviral therapy. Especially the lamivudine resistance mutations
rtL180M/rtM204V and rtM204I were detected.
Conclusion: This study shows the distribution of HBV genotypes, therapy resistance, and vaccine escape mutations in HBV-
infected patients in Oman. Our findings will have a major impact on therapy management and diagnostics of chronic HBV
infections in Oman to control HBV infection in this intermediate HBV-endemic country.
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Introduction
Despite the introduction of a safe and effective vaccine against
hepatitis B virus (HBV) in 1982, hepatitis B remains a global
public health burden resulting in more than 600,000 deaths
worldwide per year [1]. Clinical manifestations of HBV infection
range from inapparent infection to fulminant hepatic failure.
Chronic infection develops in approximately 5% of immunocom-
petent HBV-infected adults, but up to 100% of infected newborns
may become HBV carriers. The long-term consequences of
chronic HBV infection include liver cirrhosis and hepatocellular
carcinoma (HCC). These life-threatening liver disease complica-
tions can affect 15%–40% of HBV carriers who acquired the virus
early in life [2,3].
Eight HBV genotypes (A–H) have been described based on
nucleotide divergence over the entire genome sequence of more
than 8% [4,5]. HBV genotypes have distinct geographic
distribution, with genotype A found predominantly in Northwest
Europe, North America, and Central and sub-Saharan Africa;
genotypes B and C in Southeast Asia, China, and Japan; genotype
D in the Mediterranean, the Middle and Far East, and India;
genotype E in Africa; genotype F in Native Americans, Polynesia,
and Central and South America; genotype G in the United States
and France; and genotype H in Central America [5–7]. Africa is
one of the highly endemic regions for HBV, with five HBV
genotypes (A–E) predominating [8]. HBV genotypes show not
only distinct geographic distribution but even within regions prove
to be an invaluable tool in tracing the molecular evolution,
patterns, and mode of spread of HBV [9]. The natural history of
chronic hepatitis B (CHB) differs between HBV genotypes with
regard to progression to liver fibrosis and development of HCC
[10–14]. In addition, HBV genotypes differ in their response to
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antiviral treatment, e.g. susceptibility to interferon-alpha is greater
in HBV genotype A-infected patients than in those infected with
genotypes D, B, and C [15]. In contrast, the response to treatment
with nucleoside/nucleotide analogues is rather independent of
HBV genotypes [16,17] and can possibly influence vaccination
efficacy against HBV [18].
Oman is a country with an intermediate prevalence of HBV
carriers (2.8–7.1%) [19,20]. According to a retrospective study
conducted in 2010 using serum samples collected for the World
Health Survey, it was observed that the prevalence of HBV
infection in the Omani population over all age groups was 5.8%
(unpublished data). In 1990, Oman implemented vaccination of all
newborns according to the WHO recommendation [1]. The
impact on vaccination efficacy and coverage was evaluated in
2005 in a nationwide survey, showing that 15 years after
introduction of HBV vaccination of newborns the prevalence of
CHB in children dropped from 2.3% in 1990 to 0.5% in 2005
[21].
Little is known about HBV genetic diversity including genotype
distribution, the prevalence of antiviral resistance, and surface
antigen vaccine escape mutations in circulation in Oman.
Therefore, we determined the prevalence of HBV genotypes
among individuals who have been tested positive for HBsAg.
Furthermore, we explored the prevalence of ‘‘a’’ determinant




One hundred seventy-nine chronically HBV-infected patients
were included in this study. All HBsAg-positive patients were out-
patients and were enrolled at three tertiary hospitals, the Royal
Hospital, Khoula Hospital, and Armed Forces Hospital in Muscat
and additionally at eleven regional hospitals (Sohar H., Suweiq H.,
Rustaq H. [all in Batinah]; Buraimi H. [Buraimi]; Nizwa H., [Al
Dhakhliya]; Ibri H. [Dhahira]; Salalah H. [Dhofar]; Khasab H.
[Musandam]; Ibra H., Sur H. [both in Sharqiya]; and Haima H.
[Wosta]) to represent the whole Sultanate of Oman. Since the
patient samples of this study were obtained from out-patients, no
information on treatment history was available. All patients were
confirmed positive for HBsAg and negative for anti-HCV and
anti-HDV. Serum samples were collected from the HBsAg-
positive patients and stored at 280uC until use.
Ethical Approval
The study was approved by the ethical committee of the
Ministry of Health, Oman. Informed written consent was given by
all participants.
Serological Markers
Serological markers for HBV profiles for HBV antigens
(HBsAg, HBeAg) and antibodies (anti-HBc IgM, anti-HBc IgG,
and anti-HBe) were determined using commercially available one-
step enzyme immunoassay kits (Monolisa, Bio-Rad, Hercules, CA,
USA), Anti-HCV was determined using Murex version 4.0
(Abbott Laboratories, Abbott Park, IL, USA) and anti-HDV
IgG/IgM using ELISA assays (DRG International, Springfield,
NJ, USA). All serological approaches were carried out following
the manufacturers’ instructions.
Nucleic Acid Extraction
Nucleic acid was extracted from 200 ml of patient sera using the
QIAamp DNA extraction kit (Qiagen, Hilden, Germany) follow-
ing the manufacturer’s instructions, subsequently diluted in 10 ml
aliquots and stored at 280uC until use.
Detection of HBV Genomes
The presence of HBV genomes was determined using HBV-
specific nested PCR as described previously [22] with minor
modifications. HBV primer sequences are described in Table 1. In
brief, the first PCR was performed using sense primer HBV-022
and antisense primers HBV-065 and HBV-066. The nested PCR
was carried out using primer HBV-024 and antisense primers
HBV-041 and HBV-064 which amplified a 332 bp fragment
spanning from nt455 to nt786 (numbering according GenBank
accession number HM011485). PCR was performed with 5 ml of
isolated nucleic acid, 200 nM of each primer and the HotStarTaq
Master Mix Kit (Qiagen, Hilden, Germany). Thermal cycling
parameters were initial denaturation at 94uC for 15 min, followed
by 35 cycles of 30 sec at 94uC denaturation, 30 sec at 52uC
annealing, and 45 sec at 72uC extension, followed by a final
extension of 5 min at 72uC. Cycling parameters for the second
PCR remained the same as in the first one except that the number
of cycles was increased to 40. PCR products were analyzed on
1.5% tris-borate-EDTA (TBE) agarose gels. Serum HBV DNA
from a patient with a high HBV titer diluted into 1.000 copies/5 ml
as positive control (generous gift from Prof. Wedemeyer,
Hannover Medical School, Hannover, Germany) and an HBV-
negative control were included in any run. The nested PCR was
evaluated with HBV QCMD panels HBVDNA11A and
HBVGT11 for HBV detection and genotyping, respectively
(Quality Control for Molecular Diagnostics, www.qcmd.org).
Each sample was tested at least in duplicate. Sample processing
(DNA/RNA extraction, template preparation, and master-mix
preparation) and PCR were done in separate laboratory rooms
which are all certified for molecular diagnostics using standard
precautions to prevent assay contamination.
Identification of HBV Genotypes and Genotype Mixtures
HBV genotypes were determined by direct sequencing of HBV-
specific amplicons of the HBV S gene obtained by the HBV
detection PCR. Nested PCR products were purified using the Exo
SAP-IT kit (USB Corporation, Cleveland, OH, USA) according to
the manufacturer’s instructions. Sequencing reactions were
performed using 1–5 ml of purified PCR products, 1 ml of BigDye
reaction mix (Life Technologies/Applied Biosystems, Darmstadt,
Germany), and 0.5 mM of primers HBV-024 and HBV-025,
respectively. Obtained sequences were manually edited and
analyzed using BioEdit 9.7 (http://www.mbio.ncsu.edu/bioedit/
bioedit.html) and Geneious Pro software (Version R6, Biomatters
Ltd, Auckland, New Zealand). For genotyping, phylogenetic
analysis with corresponding sequences of nine HBV reference
sequences, representing the eight HBV genotypes A to G, was
performed using the MEGA 5 software [23]. The molecular
evolution was inferred by using the Neighbor-Joining method with
1,000 bootstrap replicates. Evolutionary distances were computed
using the Maximum Composite Likelihood method [23]. For
independent confirmation, the genotyping online tool at http://
www.hepseq.org was utilized. HBV reference strains in GenBank
were HBV-A: HM011485, X02763; HBV-B: D00329; HBV-C:
X01587; HBV-D: V01460; HBV-E: X75657; HBV-F: X75658;
HBV-G: AF16050; and HBV-H: AY090457 (Fig. 1).
HBV genotype mixtures were discovered by aligning sequences
from the genotyping PCR with sequences from the mutational
analysis. Obvious sequence differences, not explainable as
occurrence of quasi-species, were analyzed separately and
confirmed by sub-cloning and sequencing. Sub-cloning was
HBV Genotype Prevalence in Oman
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performed using TOPO TA Cloning Kit and Top10 competent
cells (Life Technologies/Applied Biosystems, Darmstadt, Ger-
many) following the manufacturer’s instructions. At least 10 clones
were sequenced for identifying HBV genotype mixtures.
In order to identify possible HBV genotype recombination, all
HBV sequences were analysed using the Recombination Detection
Program (version 4.22) as described recently [24].
Determination of Antiviral HBV Resistance and HBV
Vaccine Escape Mutations
Presence of HBV antiviral therapy resistance mutations and
HBV vaccine escape mutations was determined by established in-
house PCR and subsequent sequencing. In brief, in the first PCR
round the HBV consensus primer pair HBV-069 and HBV-070
was used. For the nested HBV PCR sense primer HBV-001 and
antisense primer HBV-017 were used for amplifying a 1143 bp
fragment spanning from nt57 to nt1199 (numbering according to
HM011485). Amplified fragments were purified using the Exo
SAP-IT kit (USB Corporation, Cleveland, OH, USA) and
sequenced using primers HBV-001, HBV-025, and HBV-017.
Fully overlapping sequences from primers HBV-001 and HBV-
025 were used to discover escape mutations, while sequences
obtained with primers HBV-001 and HBV-017 were analyzed to
determine antiviral resistance. Sequences were manually edited,
aligned with prototype reference sequences (accession numbers for
the HBV prototypes are shown in Fig. 2 and 3), and translated into
amino acid sequences using the Geneious Pro software (Version
R6, Biomatters Ltd) to identify amino acid substitutions. All
primer sequences are listed in Table 1.
The 288 bp fragment located between nt479 and nt766 coding
for amino acid (aa) 109–204 of the HBsAg and the 858 bp fragment
between nt208 and nt1065 coding for aa 27–286 of the reverse
transcriptase (rt) domain of the HBV polymerase were used for the
analysis of drug resistance mutations and vaccine escape mutations,
respectively. 146 sequences of this analysis were submitted to
GenBank (accession numbers: KJ585434–KJ585579).
Statistical Analysis
Statistical analysis was performed using SPSS release 20 (IBM
Corporation, Armonk, NY, USA) and Prism5 software (version
5.01, GraphPad Software, San Diego, CA, USA, www.graphpad.
com). Categorical variables were compared by Fisher’s exact test.
Continuous quantitative variables were compared by using the
Mann-Whitney U test, with a 2-tailed p-value ,0.05 considered to
be statistically significant.
Results
Baseline Characteristics of the HBsAg-positive Omani
Patients
One hundred seventy-nine HBsAg-positive out-patients from
Oman were included in this study. 54/179 (30.17%) of the patients
were female and 124/179 (69.27%) were male; for one patient no
gender information was available. The median age of patients was
35 years (range: 18–60 years). Median serum HBV loads of the
patients ranged from 1.08 log10 to 7.04 log10 HBV IU/ml. The
baseline characteristics of the patients are summarized in Table 2.
Prevalence and Geographic Distribution of HBV
Genotypes in Oman
Serum samples from 179 HBsAg-positive patients were
collected in all nine governorates at 14 gastroenterologic clinics,
representative for the whole Sultanate of Oman according to its
population density with approximately 90% of inhabitants living
in the North. 146 (81.6%) samples were from the northern and 33
(18.4%) samples from the southern part of Oman.
HBV genomes were detected by PCR in 170 samples (137 in
the northern and 33 in the southern regions). Sequencing of PCR
products and subsequent phylogenetic analysis were performed to
determine HBV genotypes. Of all circulating HBV genotypes,
genotypes D (130/170; 76.47%) and A (32/170; 18.28%) are
predominant in Oman. HBV genotypes C (2/170; 1.18%) and E
(2/170; 1.18%) were less frequent and the HBV genotypes B, F, G,
and H were not detected (Fig. 1). Noteworthy, four patients
(2.35%) showed HBV genotype mixtures implying double
infections (patient numbers 106, 123, 124, and 142). Three of
these patients were infected with HBV genotypes A and D, and
patient #106 was infected with HBV genotypes C and D (Fig. 1).
No HBV genotype recombination could be detected in the
analysed patient samples.
Comparison of the HBV genotype distribution between the
North and the South of Oman revealed only minor differences. In
the northern region the prevailing HBV genotype was D (107/
137; 78.10%), followed by genotype A (23/137; 16.79%),
including 3/137 (2.19%) HBV D/A genotype mixtures, and two
(1.46%) of each HBV genotypes C and E. HBV genotypes D (23/
33; 69.70%) and A (9/33; 27.27%) were also the prevalent HBV
genotypes in the South of Oman, and only one isolate (3.03%)
represented HBV genotype mixtures (HBV D/C).
Prevalence of HBV Vaccine Escape Mutations in HBsAg-
positive Omani Patients
In order to determine the prevalence of HBV vaccine escape
mutations circulating in Oman, mutational analysis was performed
on the 170 HBV isolates. Major vaccine escape mutations have
been described to be located in the ‘‘a’’ determinant of the small
surface protein (SHBsAg, aa 124–147). We therefore analyzed the
HBV sequences of the surface gene of the HBV genome from
nt497 to nt635, coding for aa115 to aa160 of SHBsAg (numbering
is according to GenBank accession number HM011485). Of
the170 HBV isolates, 148/170 (87.06%) showed wild-type
sequences, while 22/170 (12.94%) HBV surface antigen sequences
showed mutations in the HBsAg gene. In particular, mutations at
Table 1. HBV-specific primers for detection, genotyping, and
mutational analysis.
N6 Name Sequence 59-39 Position
1. HBV-022 TGCTGCTATGCCTCATCTTC 414–433
2. HBV-065 CAAAGACAAAAGAAAATTGG 822–803
3. HBV-066 CACAGATAACAAAAAATTGG 822–803
4. HBV-024 CAAGGTATGTTGCCCGTTTGTCCT 455–478
5. HBV-041 GGACTCAMGATGYTGTACAG 786–767
6. HBV-064 GGACTCAMGATGYTGCACAG 786–767
7. HBV-069 CCTGCTGGTGGCTCCAGTTC 56–75
8. HBV-070 CGCAGTATGGATCGGCAGAGG 1275–1255
9. HBV-001 CTGCTGGTGGCTCCAGTTCAGGA 57–79
10. HBV-017 GGGGTTGCGTCAGCAAACACT 1199–1179
11. HBV-025 GGTATAAAGGGACTCACGATG 795–775
Nucleotide position is according to the HBV reference strain GenBank accession
number HM011485.
doi:10.1371/journal.pone.0097759.t001
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aa positions 118–120, 125–128, 130, 133–135, and 143 were
observed. Sixteen patients showed only one mutation, and three
patients showed two and three mutations, respectively, in the ‘‘a’’
determinant region (Fig. 2 and Table 3).
The classical diagnostic/vaccine escape mutations, G145R and
D144E, could not be detected. However, the well-described
vaccine escape mutation P120T was found in two sequences of
HBsAg-positive patients (samples 43 and 88) while both of them
could be related to HBV genotype D (Fig. 2 and Table 3). Other
possible vaccine escape mutations were detected at positions T126
(T126S) and M133 (M133T); however, their impact on vaccine
escape is under discussion. Further identified S-gene mutations are
not associated with diagnostic and vaccine escape and were S-gene
variants.
The distribution of HBV escape mutations of HBV isolates from
different regions of Oman, gender, HBV genotypes, the status of
HBeAg and anti-HBe, age, and HBV load is displayed in table 4.
No correlation was found for geographic distribution, gender,
HBV genotype, status of HBeAg and anti-HBe, age and HBV load
of escape mutations detected in the HBsAg-positive samples from
the north compared to the south of Oman (p.0.5).
Figure 1. Phylogenetic analysis of Omani HBV strains. Phylogenetic analysis inferred from distance analysis (Kimura 2 parameters model) and
neighbor-joining reconstruction from a partially overlapping region of P and S genes (from nt479 to nt766) of 170 Omani HBV DNA-positive isolates.
The reference strains were denoted by HBV genotype and ‘‘N’’ signal with the GenBank accession number, respectively (for example: ‘‘A-
HM011485N’’). The Omani samples were numbered, and especially the double-infected samples were highlighted by the ‘‘&’’ signal. (The numbers
at the nodes indicate bootstrapping values.).
doi:10.1371/journal.pone.0097759.g001
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Figure 2. Analysis of escape mutants of Omani HBV isolates. The amino acid sequences in the ‘‘a’’ determinant region of the Omani escape
mutant isolates were aligned with the corresponding region of the reference sequences (HBV-genotypes A to H; GenBank accession numbers are
denoted) by ClustalW with Neighbor Joining method and 1000 bootstrap replicates. Amino acid substitutions were highlighted.
doi:10.1371/journal.pone.0097759.g002
Figure 3. Analysis of antiviral therapy resistant mutations of Omani HBV isolates. The amino acid sequences of the HBV polymerase
(reverse transcriptase region; aa rtM1 to rtL275) of the Omani resistant mutation isolates were aligned with the corresponding region of the reference
sequences (HBV-genotypes A to H; GenBank accession numbers are denoted) by ClustalW with Neighbor Joining method and 1000 bootstrap
replicates. Described antiviral resistant mutations were highlighted and denoted at the top (e.g., L80V).
doi:10.1371/journal.pone.0097759.g003
HBV Genotype Prevalence in Oman
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Prevalence of HBV Resistance Mutations to Antiviral
Therapy
Chronically HBV-infected patients in Oman were treated with
nucleotide/nucleoside analogues (NA) according to European/
American guidelines. To identify the antiviral therapy resistance
mutations, the obtained Omani patient sequences located between
nt130 to nt954 coding aa rtM1 to rtL275 (numbering is according
to GenBank accession number HM011485) were aligned with the
corresponding regions of reference sequences and subsequently
translated into aa sequences. Of 170 HBV DNA-positive samples,
146 were successfully sequenced using the primer pair HBV-001
and HBV-017. Mutational analysis showed that eight of the 146
HBsAg-positive patients (5.48%) exhibit NA resistances. Among
them seven patients had lamivudine resistance mutations (LAM)
and one had the adefovir resistance mutation (ADV; S85A of
patient #155) (Fig. 3). Notably, one patient (patient #069) showed
four mutations (L80V, L180M, M204V, and Q215S) and patient
#049 three mutations (L80V, L180M, and M204V). The N236T
adefovir dipivoxil resistance mutation and other previously
described resistance mutations against other antiviral drugs (e.g.
entecavir, telbivudine) could not be detected in the HBsAg-positive
patients.
The distribution of antiviral resistance mutations of HBV
isolates from different regions of Oman, gender, HBV genotypes,
the status of HBeAg and anti-HBe, age, and HBV load were
analyzed and are displayed in table 5. A correlation could be
identified showing that drug resistance mutations were significant-
ly more abundant in anti-HBe-negative individuals (one tailed
Fisher’s exact test, p = 0.045). However, no correlation could be
detected for geographic distribution, gender, HBV genotype,
HBeAg status, age, and viral load (p.0.5).
Discussion
The prevalence of HBV infection varies to a great extent in
different areas and countries, depending on a number of factors
that include implementation of the HBV vaccination program,
screening of blood samples from blood donors, or education of the
population about the risk factors for HBV infection. Oman, a
country with intermediate HBV carrier prevalence of 2–7%, has
implemented HBV vaccination of all newborns in the country for
the local population and immigrants free of charge in 1990.
However, little is known about the prevalence of HBV genotypes,
Table 2. Clinical profiles of HBsAg-positive patients of Oman.
Variables Values
Median age (y) 35y (18–61 years)
Sex (male/female) 124/54
HBV load (log10 IU/ml) 1.08 to 7.04
HBsAg positive 179/179 (100%)
HBeAg positive 7/179 (3.91%)
HBeAg negative 120/179 (67.04%)
anti-HBeAg positive 120/179 (67.04%)
HBeAg and anti-HBeAg negative 4/179 (2.23%)
doi:10.1371/journal.pone.0097759.t002
Table 3. Mutations in the ‘‘a’’ determinant domain of Omani HBV isolates.
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HBV resistance mutants to antiviral drugs, and HBV vaccine
escape mutants in circulation in Oman.
Increasing evidence supports the view that different HBV
genotypes have a significant role in determining the clinical
outcome of liver diseases and the response to antiviral therapies
[14,25–27]. Accordingly, in this study we have analyzed the
geographic distribution of HBV genotypes and the prevalence of
vaccine escape and antiviral treatment resistance mutants of 179
Table 5. Distribution of antiviral resistance mutations.
No mutation Resistance mutations
Count Mean Median Count Mean Median
Region North 111 – – 6 – –
South 27 – – 2 – –
Gender F 40 – – 3 – –
M 98 – – 5 – –
Age 138 37 33 8 37 34
HBeAg ND 2 – – 0 – –
Neg 69 – – 2 – –
Pos 67 – – 6 – –
Anti-HBe* ND 2 – – 0 – –
Neg 69 – – 7 – –
Pos 67 – – 1 – –
Genotype A 28 – – 2 – –
C 2 – – 0 – –
D 107 – – 6 – –
E 1 – – 0 – –
Viral loada 138 4,50 4,43 8 5,44 5,90
*denotes p,0.05; aValues are given as log10 international units (IU)/ml; ND: Not done; F = female, M = male.
doi:10.1371/journal.pone.0097759.t005
Table 4. Distribution of S-gene variants of Omani HBV isolates.
No mutation S-gene mutations
Count Mean Median Count Mean Median
Region North 118 – – 19 – –
South 30 – – 3 – –
Gender F 46 – – 6 – –
M 102 – – 16 – –
Age 148 37 33 22 44 41
HBeAg ND 3 – – 1 – –
Neg 72 – – 9 – –
Pos 73 – – 12 – –
Anti-HBe ND 3 – – 1 – –
Neg 77 – – 12 – –
Pos 68 – – 9 – –
HBV Genotype A 27 – – 5 – –
C 1 – – 1 – –
D 114 – – 16 – –
D-A 3 – – 0 – –
D-C 1 – – 0 – –
E 2 – – 0 – –
Viral loada 148 4,55 4,56 22 4,03 3,52
aValues are given as log10 international units (IU)/ml; ND: Not done; F = female, M = male.
doi:10.1371/journal.pone.0097759.t004
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HBsAg-positive patients from 14 gastroenterology clinics of
geographically distinct regions of Oman. All patients were out-
patients and were enrolled in hospitals throughout Oman. This
patient cohort might be representative of the general HBsAg-
positive population of Oman. Of 179 HBsAg-positive patients,
HBV DNA was detected in 170 patients (94.97%). Molecular-
epidemiologic analysis enabled the detection of four of the eight
HBV genotypes, namely genotypes A, C, D, and E, with a
predominance of genotypes A (18.28%) and D (76.47%). This is in
accordance with previous studies of HBV genotype distribution in
other regions of the Middle East and neighboring countries or
those in close contact to Oman. HBV genotype D is predominant
in neighboring countries Saudi Arabia (81.4%) and the Republic
of Yemen (90%), but also prevalent in Egypt, Turkey, Iran, and
Tunisia [28–33].
Few studies have reported the occurrence of mixed HBV
genotype infections and the effect of double infections on the
clinical outcome or on viral replication [14,34]. We found HBV
genotype mixtures in 4 out of 170 (2.35%) serum samples, in
particular three with HBV-A/D and one with D/C. Notably, no
HBV genotype recombination could be detected in the Omani
HBV isolates. The prevalence of mixed HBV genotype (2.35%)
found in Oman was low when compared to other studies from
Asia, where 10.6% (Eastern China) [35] and 16.9% (Vietnam)
[14] of the hepatitis B patients revealed HBV genotype mixtures.
This may be due to the low prevalence of HBV in this country
(2%–7%) in contrast to regions in Asia with a high prevalence, like
China with about 10% [36] and Vietnam with up to 20% [37] of
HBsAg-positive individuals. However, the high vaccination
coverage might also have had an impact on the infection pattern
observed in Oman.
The common hepatitis B vaccines contain the major HBsAg
protein that induces immune response to the major hydrophilic
region (MHR), the so called ‘‘a’’ determinant which maps to aa
residues 100–160 of the HBV surface protein [38]. Various
vaccine/immune and diagnostic escape mutations have been
described which are detectable mainly in the most antigenic MHR
located in the region of aa120–aa147 [39–44]. The best-described
and stable vaccine escape mutations are the sG145R, sD144E/A,
and sP120T mutations [45,46]. HBsAg mutations in the ‘‘a’’
determinant can lead to conformational changes with altered
antigenicity and failure to neutralize the virus, to escape diagnostic
assays, and are associated with liver disease progression like
fulminant hepatitis, cirrhosis, and HCC [43,46–48]. The occur-
rence of HBsAg mutations is mainly caused by vaccine and/or
hepatitis B immunoglobulin (HBIG) administration, natural
selection by the host immune response, and antiviral therapy
pressure inducing antiviral resistance mutants which alter simul-
taneously the amino acid composition of the surface antigen [49–
51]. Of the 170 HBV isolates analyzed, 148 (87.06%) showed
wild-type sequences and only 22 (12.94%) revealed mutations in
the HBsAg gene and of these two isolates (1.1%) showed the
described vaccine escape mutation sP120T. Other vaccine escape
mutations, especially the G145R and D144E/A mutation, could
not been detected. Our result is in good agreement with recent
reports revealing a prevalence of HBsAg vaccine escape mutations
of 0.7% to 28% depending on the region, age of HBV-infected
individuals, and endemicity of HBV [42,48,52]. The low
frequency of vaccine escape mutations implies that there is
obviously no threat to the HBV vaccination program in Oman.
However, a surveillance program to observe the situation of
circulating HBV escape mutations in Oman is needed to
determine the prevalence of HBV escape mutations more
comprehensively. Most of the mutations detected in the ‘‘a’’
determinant of the HBV isolates from the patients of Oman were
located in loop 1 (B cell epitope; aa118–120, 126–128, 130, and
133–135). Of these, the well-characterized sP120T mutation could
be detected in 2/170 HBV-infected patients. The identified sT/
S143L/M mutations of the HBsAg gene, mapped to loop 2 of the
‘‘a’’ determinant, and were thought to be associated with
vaccination allowing ongoing replication of HBV [53]. However,
in this domain (loop 2) the most prominent vaccine escape
mutations sG145R and sD144E/A were not found in the patient
collective. Mutations in the S-gene region between aa 120 and
145 have been discussed to affect the antigenic structure of the
HBsAg. We found the sP120T, sT126S, sM133T, and sT/S143L/
M mutations in the HBsAg-positive patients while these mutations
have been previously described as possible vaccine escape
mutations (reviewed in: [54]). However, these mutations were
less frequent (4.1%). Other mutations detected in the S-gene of
the patient isolates have not been described as escape mutations
so far and therefore could be classified as ‘‘a’’ determinant
variants.
Besides interferon-alpha, at present five nucleoside/nucleotide
analogues (NAs) have been introduced worldwide for treatment of
chronic hepatitis B (CHB) targeting the viral polymerase (reverse
transcriptase, RT). Of these, lamivudine (LAM, 3TC) was the
antiviral drug first approved in 1995. Although the introduction of
NAs for therapy of CHB significantly reduces disease progression
and efficiently controls HBV replication, unfortunately, NAs can
select resistance mutations in the HBV RT-domain which is a
major limiting factor for long-term viral suppression [55]. For
LAM the prevalence of resistance mutations rapidly rises up to
80% after four years of treatment. The other NAs, adefovir
dipivoxil, entecavir, telbivudine, and tenofovir disoproxil, show
higher genetic barriers with a resistance development for tenofovir
of 0% to 5.9% after treatment for three years [39]. Besides other
previously described resistance mutations, the best-described drug
resistance mutations are the LAM resistance mutations rtL180M
and rtM204V/I and the adefovir resistance mutations rtA181V/T
and rtN236T [39]. The LAM mutations rtM204V/I are mapped
to the catalytic center of the viral RT domain, the YMDD motif.
Although we had no information on hand how many and which
ones of the 170 CHB patients of our study have been under anti-
viral treatment and which NA therapy was used, we found 5.48%
NA-resistance mutations, seven of them conferring resistance to
LAM. One patient was determined to have the suspected adefovir-
resistant mutation (rtS85A). Other antiviral therapy resistance
mutations, such as rtA181V/T or rtN236T, were not detected.
According to the guidelines on the management of chronic
hepatitis B, in the case of resistance to LAM and also ADV the
therapy should be switched or add-on to a nucleotide analogue
treatment option like tenofovir disoproxil fumarate [56]. The
relatively low rate of approx. 5.48% LAM-resistant patients is in
agreement with a recent report from the US showing ,2% in
untreated CHB patients [57].
Further analysis showed that there was no statistical correlation
between the geographic distribution, gender, age, HBV genotypes,
status of HBeAg and anti-HBe, and HBV load of the vaccine
escape and resistance mutations if comparing HBsAg-positive
samples from the north with the south of Oman. However, a
significant correlation between the anti-HBe status (anti-HBe
negative) and the frequency of antiviral resistance mutations could
be identified. This finding may suggest that anti-HBe-negative
individuals might be more likely to develop resistance mutations.
However, this finding has to be proven in further studies in more
detail.
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In conclusion, this study shows for the first time the prevalence
and geographic distribution of HBV genotypes in Oman, with a
predominance of HBV genotypes D and A. HBV genotype
mixtures of A and D were also observed to a low extent.
Mutational analysis of the HBV isolates revealed a low prevalence
of vaccine escape mutants in the HBsAg-positive patients which is
indicative of the effectivity of the HBV vaccination program in
Oman. The incidence of antiviral therapy resistance mutations of
the CHB patients was low; however, the identification of LAM
and ADV resistance mutations recommend the adjustment of the
therapy management to international guidelines. Our findings will
therefore have major impact on the therapy management and
diagnostics of CHB patients in Oman.
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